Strategic partnerships Genomics collaborates with leading life sciences companies such as Novo Nordisk and Vertex, signaling openness to deep, long-term partnerships that can expand its client base in pharma and biotech.

Transatlantic footprint With offices in the UK and US and labs in Massachusetts, Genomics presents a cross-border sales opportunity to engage North American and European life sciences customers seeking scalable genomic prevention solutions.

Clinical and systems value Proprietary algorithms link genomic variation to thousands of biological measurements and disease outcomes, offering both clinician-oriented risk insights and population-level healthcare system benefits that can be monetized across drug development, prevention, and screening programs.

Growth and capacity A workforce of over 150 highly qualified scientists and engineers supports a scalable product suite, enabling many potential use cases from predictive risk to personalized screening, which can drive multi-product upsell with existing clients.

Market positioning Genomics positions itself as a leader in genomic prevention and preventative medicine, presenting a compelling narrative for pharma partnerships and health system collaborations focused on early intervention and improved outcomes.